The stock's fall snapped a three-day winning streak.

Shares of Catalyst Pharmaceuticals Inc. CPRX rallied 2.80% to $22.05 Friday, on what proved to be an all-around positive ...

KeyBanc analyst Scott Schoenhaus lowered the firm’s price target on Health Catalyst (HCAT) to $5 from $7 and keeps an Overweight rating on the ...

We recently published a list of 11 Best Russell 2000 Stocks to Buy According to Wall Street Analysts. In this article, we are ...

Pratteln, Switzerland, April 16, 2025 – Santhera Pharmaceuticals (SIX: SANN) announces the latest progress on the commercial rollout of AGAMREE® for the treatment of Duchenne Muscular Dystrophy (DMD).

This study presents an innovative approach to single-atom catalysts, overcoming oxidative addition challenges in cross-coupling reactions for pharmaceuticals.

OpenAI declined to comment, while Windsurf, formerly known as Codeium, did not immediately respond to a Reuters request for ...

What Johnson & Johnson and Eli Lilly are saying about Trump’s pharmaceutical tariffs, and Dexcom scores FDA approval for its ...

The development of new antibiotics to treat superbugs and other bacterial infections is a global priority, with the rate of infections that cannot be treated with current antibiotics rising and ...

BERLIN, April 10, 2025--(BUSINESS WIRE)--Regulatory News: TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company focused on developing novel therapies for treatment ...